Raanana, Israel - Polyrizon Ltd. (NASDAQ:PLRZ), a biotech firm in the development stage, has filed a divisional patent application in Israel for its Trap & Target (NYSE:TGT) (T&T) platform technology.

Dr. Chen is developing a new delivery system which is designed to help cancer drugs cross the blood-brain barrier.

The filing represents Polyrizon's ongoing efforts to protect its intellectual property and strengthens the company's position in the field of advanced nasal drug delivery. The T&T platform boasts ...

Microbes that reside peaceably in the nasal passageways and on the skin can be harnessed for taking drugs to target cells.

This application focuses exclusively on protecting the Company’s advanced intranasal drug delivery system ... Prevention of Dripping: The system is designed to prevent the formulation from dripping ...

A nasal vaccine for COVID-19—based on technology developed at Washington University in St. Louis—is poised to enter a phase 1 ...

A new nanomedicine drug delivery system improves chemotherapy targeting for choriocarcinoma, shrinking tumors by 95% in mouse models. Researchers engineered polymersomes to enhance methotrexate (MTX) ...

A new nasal delivery method for amifostine could protect healthy tissue during pancreatic cancer radiation therapy, ...

Polyrizon (PLRZ) announced the filing of a divisional patent application with the Israel Patent Office for its Trap & Target platform ...

RALEIGH, NORTH CAROLINA / ACCESS Newswire / January 21, 2025 / Belhaven Biopharma, a leader in dry powder nasal drug delivery systems, announces the launch of a new clinical study designed to evaluate ...

This application focuses exclusively on protecting the Company’s advanced intranasal drug delivery ... The system is designed to prevent the formulation from dripping out of the nasal cavity ...